Defining Sensitivity and Overcoming Resistance to PARP Inhibition in Pancreatic Ductal Adenocarcinoma Using Combined Genomics and Metabolomics Tools
Grant Amount: NIS 4.9 Million
About the Project
Pancreatic cancer is a malignant disease that typically does not respond well to conventional therapy. Recently, a sub-group of pancreatic cancer patients, in whom the tumors are deficient in a genetic repair mechanism, was characterized. Consequently, these tumors respond better to DNA-damage-inducing drugs. Nevertheless, these tumors also rapidly develop resistance to treatment. By combining genetics and biochemistry, the research will map the metabolic profile of these tumors, in order to decipher mechanisms of resistance to therapy and identify ways to overcome them.
Research Team
Prof. Eyal Gottlieb
Technion – Israel Institute of Technology (Ruth and Bruce Rappaport Faculty of Medicine)
Dr. Yaacov Richard Lawrence
Sheba Medical Center (Radiation Oncology)
Dr. Keren Yitzhak
Technion – Israel Institute of Technology (Faculty of Medicine)
Dr. Talia Golan
​Sheba Medical Center (Oncology Institute)
More Projects Funded